anti-CD19/CD28 bispecific antibody RO7443904

A bispecific antibody directed against both the tumor-associated antigen (TAA) CD19 and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD28 bispecific antibody RO7443904 targets and binds to both CD28 expressed on T cells and CD19 expressed on tumor cells, which crosslinks the T cells to the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against the CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.